share_log

Eterna Therapeutics Launches Research To Evaluate ERNA-101's Ability To Induce And Modulate Antitumor Immunity In Ovarian And Breast Cancer Models

Eterna Therapeutics Launches Research To Evaluate ERNA-101's Ability To Induce And Modulate Antitumor Immunity In Ovarian And Breast Cancer Models

以心元治疗学公司展开研究,评估ERNA-101在卵巢和乳腺癌模型中诱导和调节抗肿瘤免疫的能力
Benzinga ·  12/03 21:38

Eterna Therapeutics Launches Research To Evaluate ERNA-101's Ability To Induce And Modulate Antitumor Immunity In Ovarian And Breast Cancer Models

Eterna Therapeutics启动研究,以评估ERNA-101在卵巢癌和乳腺癌模型中诱导和调节抗肿瘤免疫的能力

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发